We are monitoring the impact of COVID-19 on Latin America Hemophilia Management Market Get in touch with us for detailed analysis Know More
Share on

Latin America Hemophilia Management Market Research Report – Segmented By Type, Drug & By Country (Mexico, Brazil, Argentina, Chile & Rest of Latin America) – Analysis on Size, Share, Trends, Growth, Forecasts (2022 to 2027)

Published: January, 2022
ID: 274
Pages: 137

Latin America Hemophilia Management Market Size & Growth (2022 to 2027)

As per the report, the size of the Latin America Hemophilia Management Market was worth USD 650.82 million in 2022 and estimated to be growing at a CAGR of 1.69%, to reach USD 707.70 million by 2027.

The hemophilia management market has a lot of potential due to advances in gene therapy and the impending approval of drugs to treat hemophilia. In addition, the increased manufacture of recombinant factor concentrates has enabled new treatment options for hemophilia, overcoming the lack of plasma-derived concentrates. Research and analysis focus on upcoming industry trends and provide insights to help businesses identify market opportunities and establish a strategic plan to improve their market positions.

The increasing cases of genetic disorders, the proliferation of hemophilia, and the growing use of recombinant products drive the hemophilia management market in Latin America. In addition, the technological and new advancements are coagulating aspects that are also propelling the hemophilia management market forward. Also, according to the CDC, the typical age for hemophilia diagnosis is 36 months in mild instances, eight months in moderate cases, and one month in severe cases. As a result, more disease cases are anticipated to push hemophilia treatment advancements in the future.

The demand for recombination is increasing as the number of people with hemophilia grows. In addition, consumer disposable income, healthcare spending, innovations in medical treatment, and the introduction of new trends like medical tourism are all drivers driving the hemophilia management market forward. Increasing investments in hemophilia product research and development are also propelling the market growth. 

In addition, the growing competition among the market players is expanding the regional market growth. Initiatives by the government for creating awareness among the people through medical campaigns are positively influencing the market growth. The increasing research and development activities on identifying the therapeutics agents provide lucrative growth opportunities to the market growth. One of the factors propelling the hemophilia management industry is the introduction of new drug releases. The adoption of advanced drugs and prophylaxis treatment, increasing healthcare spending, and infrastructure development are contributing to the market growth. 

However, the expansion of the hemophilia management market in the Latin American region is predicted to be hampered by a lack of awareness of the disease and the high expenses involved with its treatment. In addition, increase in the high cost of treatment and therapies available in the market because the high costs of products and therapies are out of reach for low and Middle-income families, causing them to delay treatment, limiting the market growth.

This research report on the Latin American hemophilia management market has been segmented and sub-segmented into the following categories:

By Type:

  • Hemophilia A
  • Hemophilia B

By Drug:

  • Octocogalfa
  • Nonacogalfa
  • Desmopressin
  • Other Drugs

By Country:

  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America

Geographically, Latin America is anticipated to witness a promising share in the global hemophilia management market during the forecast period. Factors such as the rising prevalence of hemophilia and the increased use of recombinant products drive the hemophilia management market in Latin America. Rising investments in research and development are also a significant factor of market expansion. Advances in gene therapy and the impending approval of medications to treat hemophilia give enormous market growth prospects in this region.

Due to the local government backing and multinational players' increased focus on these nations, the hemophilia management market in Latin America offers significant growth potential.

Argentina is a prominent market in Latin America, accounting for a considerable portion of the area due to more open investment opportunities. Brazil is also showing significant growth in the hemophilia management market due to the rising prevalence in this region. Strategic initiatives such as geographic growth and research and development are expected to be adopted by significant market players, particularly in developing regions in Latin America.

KEY MARKET PLAYERS:

Companies playing a noteworthy role in the Latin American hemophilia management market profiled in this report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, and Swedish Orphan Biovitrum AB.

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 BY Type                                        

                                5.1.1 Hemophilia A                         

                                5.1.2 Hemophilia B                          

                5.2 By Drug                                        

                                5.2.1 Octocogalfa                            

                                5.2.2 Nonacogalfa                           

                                5.2.3 Desmopressin                       

                                5.2.4 Other drugs                            

  1. Geographical Analysis

                                6.1 Introduction                               

                                6.2 Brazil                             

                                6.3 Mexico                         

                                6.4 Argentina                    

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Biogen                                          

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Pfizer Inc.                                    

                8.3 Baxter International Inc.                                       

                8.4 Bayer Pharma AG                                    

                8.5 Novo Nordisk A/S                                    

                8.6 Grifols International SA                                         

                8.7 CSL Behring                                

                8.8 Octapharma                                               

                8.9 Swedish Orphan Biovitrum AB                                           

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

    Appendix                                                          

a) List of Tables

b) List of Figures

  1. Latin America Hemophilia Management Market By Region, From 2022 - 2027 (USD Million)
  2. Latin America Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  3. Latin America Hemophilia-A Market By Region, From 2022 - 2027 (USD Million)
  4. Latin America Hemophilia-B Market By Region, From 2022 - 2027 (USD Million)
  5. Latin America Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  6. Latin America Octocogalfa Market By Region, From 2022 - 2027 (USD Million)
  7. Latin America Nonacogalfa Market By Region, From 2022 - 2027 (USD Million)
  8. Latin America Desmopressin Market By Region, From 2022 - 2027 (USD Million)
  9. Latin America Other drugs Market By Region, From 2022 - 2027 (USD Million)
  10. Brazil Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  11. Brazil Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  12. Argentina Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  13. Argentina Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)
  14. Mexico Hemophilia Management Market By Type, From 2022 - 2027 (USD Million)
  15. Mexico Hemophilia Management Market By Drug, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample